ProSomnus, Inc. - OSA STOCK NEWS

Welcome to our dedicated page for ProSomnus news (Ticker: OSA), a resource for investors and traders seeking the latest updates and insights on ProSomnus stock.

ProSomnus, Inc. Common Stock (symbol: OSA) is a leading provider of non-CPAP therapy solutions for the treatment of Obstructive Sleep Apnea (OSA). This serious medical condition affects over 1 billion people globally and is linked with several comorbidities such as heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus specializes in creating precision intraoral medical devices that are designed to fit the unique anatomy and treatment plans of each patient.

The company’s products are non-invasive, easy to use, and preferred by patients. They have demonstrated high levels of efficacy, safety, adherence, and overall positive outcomes in numerous clinical studies. ProSomnus devices are FDA-cleared, patented, and are covered by commercial medical insurance, Medicare, TRICARE, and many government-sponsored healthcare plans worldwide. This coverage extends to over 200 million lives.

Recent achievements include additional clinical research indicating that patients using ProSomnus devices have fewer apnea-hypopnea index events per hour, alongside strong treatment adherence. ProSomnus continues to develop and enhance their product offerings, providing cutting-edge solutions for those suffering from OSA.

For the latest updates, financial results, and news, contact Investor Relations or Media Relations through the provided contact details.

• Recent clinical research shows decreased apnea-hypopnea index events per hour with strong treatment adherence using ProSomnus devices.
• FDA-cleared and patented products
• Coverage by major insurance plans, including Medicare and TRICARE
• Innovative non-CPAP therapy solutions for Obstructive Sleep Apnea